BUY
|
Original-Research: Nynomic AG - from NuWays AG
Classification of NuWays AG to Nynomic AG
Muted start into the year; gradual improvements expected Topic: Nynomic published a muted start into FY25, largely the result of the ongoing uncertainty within its key end markets. Yet, management remains confident to be able to record gradual improvements throughout the year. Preliminary sales in Q1 declined by 10% yoy to € 20.6m due to unchanged wait-and-see attitude of customers and situation-related investment postponements, particularly in the semiconductor industry. As a result of the weak operating leverage, preliminary Q1 EBIT turned negative at € -0.9m (vs € 1.6m in Q1 2024). Order backlog down yoy due to fundamentally changed order behaviour. In particular, larger OEM customers have adjusted their ordering patterns in response to increased market uncertainty and reduced predictability. Instead of placing long-term blanket orders for 12 or 24 months, they are increasingly opting for shorter-term orders, such as on a quarterly basis. The € 45m order backlog at the end of Q1 (-24% yoy) is hence no major reason for concern, in our view. FY25 guidance remains unchanged. Management continues to expect € 105-110m sales (eNuW: € 108m) and € 8.5-10m EBIT (eNuW: € 9.1m) for the full year, carried by sequential improvements throughout the year, a well filled product pipeline, recent product launches, improving demand from core markets such as semiconductors, med-tech and pharma but also delayed orders materializing. Importantly, management reaffirmed its mid-term targets of €200m in sales and a 16–19% EBIT margin within 3-5 years, driven by organic growth and strategic acquisitions. This dual strategy positions Nynomic to capitalize on rising industry demand and enter a promising growth phase. While the Q1 results reflect a challenging start into 2025, we take comfort from the solid order backlog and management’s confidence in catching up over the year. Structural measures should support margin expansion beyond 2025. While the short-term visibility remains limited due to volatile customer ordering patterns, the long-term prospects remain unchanged, which is not reflected in the depressed valuation. We hence confirm our BUY rating with an unchanged € 34.5 PT based on DCF. You can download the research here: http://www.more-ir.de/d/32524.pdf For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
2133672 09.05.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.